Yamamoto T, Yasui W, Ochiai A, Ito H, Abe K, Yanaihara N, Tahara E
First Department of Pathology, Hiroshima University School of Medicine.
Jpn J Cancer Res. 1987 Nov;78(11):1169-74.
c-myc protein p62 in human gastric carcinomas was studied by immunohistochemistry using an antiserum raised against the C-terminal portion of the human c-myc gene protein. No immunoreactivity of c-myc p62 was detected in tumor cells of 27 early carcinomas, while c-myc p62-positive tumor cells were observed in 51 (36.4%) of the 140 advanced carcinomas. Many stromal cells including macrophages and fibroblasts around the tumors showed various degrees of c-myc p62 immunoreactivity. Localization of c-myc p62 was predominant in the cytoplasm of tumor cells and stromal cells. The prognosis of patients with p62-positive stromal cells was significantly better than that of patients with p62-negative stromal cells.
采用针对人c-myc基因蛋白C末端部分制备的抗血清,通过免疫组织化学方法研究了人胃癌中的c-myc蛋白p62。在27例早期癌的肿瘤细胞中未检测到c-myc p62的免疫反应性,而在140例进展期癌的51例(36.4%)中观察到c-myc p62阳性肿瘤细胞。肿瘤周围包括巨噬细胞和成纤维细胞在内的许多基质细胞显示出不同程度的c-myc p62免疫反应性。c-myc p62主要定位于肿瘤细胞和基质细胞的细胞质中。p62阳性基质细胞患者的预后明显优于p62阴性基质细胞患者。